

August 15, 2005

AnGes MG, Inc.

Basic Patent for HVJ-E Is Granted in the U.S. Covering HVJ-E
As a Foreign Gene Transferring Vector
(Patent for material, usage/transfection method and preparation process of HVJ-E)

AnGes MG, Inc. has announced that a basic patent for HVJ-E vector was granted in the U.S., and the U.S. official patent gazette (U.S. 6,913,923B2) was issued.

In basic research in gene therapy and life science, it is necessary to utilize vectors to enhance the transfection efficiency of a gene into a cell.

Virus vectors such as adenovirus and liposome are conventionally used, but many issues exist, such as their pathogenicity and toxicity, and these have been obstacles for the progress of healthcare and research.

The present invention, which focuses on the superior membrane fusion capability of Sendai virus, is a breakthrough vector technology that resolves the issues of pathogenicity and toxicity by inactivating Sendai virus and using its envelope.

AnGes MG and GenomIdea Inc., a subsidiary of AnGes MG, have been developing the present invention in collaboration, and have filed the present basic patent and also various utility patents and preparation process patents.

Chiefly, the present basic patent forms the backbone of the HVJ-E project, and was granted in the U.S., where the market is the largest.

AnGes MG has filed patent applications in Japan, Europe, Canada, Australia, China, Korea and Taiwan in addition to the U.S. for global development of the HVJ-E project, and is further establishing a strong patent network.

AnGes MG and Ishihara Sangyo Kaisha, Ltd., in alliance, have realized the commercialization of the present invention as a high performance transfection kit, GenomONE(R) in Japan, and this product has already been widely used in life science